Harrow (HROW) put vernal keratoconjunctivitis back in focus with the relaunch of VERKAZIA, a steroid sparing calcineurin inhibitor eye drop, backed by an access centric commercial push.

The VERKAZIA relaunch has come alongside a sharp improvement in recent share price momentum, with a 1 month share price return of 29.69% and a 3 month share price return of 10.41%. This is despite the year to date share price return being down 24.56% and the 5 year total shareholder return being very large, indicating long term holders have already seen substantial gains.

If this kind of turnaround story has your attention, it can be useful to see what else is setting up for a similar move through the Simply Wall St screener for 40 healthcare AI stocks

With Harrow valued at about US$1.34b and the stock trading at US$37.65, yet showing an intrinsic discount metric of 0.88, investors now face a key question: is there still value on the table, or is the market already pricing in future growth?

Most Popular Narrative: 44.9% Undervalued

Harrow's most followed narrative pegs fair value at $68.38 per share versus the last close at $37.65, framing the current price as a steep discount built on ambitious growth assumptions.

The rapidly growing demand for Harrow's portfolio of specialty ophthalmic drugs, particularly VEVYE, IHEEZO, and TRIESENCE, is positioned to accelerate further as aging populations and increased prevalence of chronic ocular diseases expand the baseline patient pool, supporting sustainable long-term revenue growth.

Read the complete narrative. Read the complete narrative.

Curious what kind of revenue curve, margin lift and future earnings power would need to materialize to support that valuation gap? The full narrative walks through the growth rates, profitability swing and future earnings multiple that underpin this fair value call, and how they tie back to Harrow's current ophthalmic portfolio and pipeline.

Result: Fair Value of $68.38 (UNDERVALUED)

However, investors still need to weigh concentration in a handful of flagship drugs, as well as execution risk around pricing and product rollouts that could challenge this upbeat setup.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

If this mix of optimism and caution resonates, take a closer look at the underlying data and test the assumptions yourself, starting with the 2 key rewards.

Looking for more investment ideas?

If Harrow is on your radar, broaden your watchlist now so you do not miss other stocks setting up compelling risk reward profiles across different themes.

• Spot potential turnarounds early by scanning 24 elite penny stocks with strong financials that already show stronger financial underpinnings than many peers.
• Target quality at a discount by reviewing the 46 high quality undervalued stocks that combine solid fundamentals with prices below estimated fair value.
• Prioritize resilience by tracking 67 resilient stocks with low risk scores that score well on balance sheet strength and volatility measures.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.